| | Course outcome | PO1 Clinician | PO2 Leader | PO3 Communicator | PO4 Lifelong learner | PO5 Professional | PO6 Critical thinker | PO7 Resear cher |
|-------|---|------------------|---------------|---------------------|----------------------------|----------------------------|----------------------------|-----------------------|
| Торіс | Acne | | | | | | | |
| DR1.1 | Enumerate the causative and risk factors of acne | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR1.2 | Identify and grade the various common types of acne | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR1.3 | Describe the treatment and preventive measures for various kinds of acne | 3 | 2 | 2 | 2 | 1 | 2 | 2 |
| Topic | Vitiligo | | | | | | | |
| DR2.1 | Identify and differentiate vitiligo from other causes of hypopigmented lesions | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR2.2 | Describe the treatment of vitiligo | 3 | 1 | 2 | 2 | 1 | 2 | 2 |
| Topic | Papulosquamous disorder | 5 | 1 * | | _ | | - | |
| DR3.1 | Identify and distinguish psoriatic lesions from other causes | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR3.2 | Demonstrate the grattage test | 3 | 1 | 3 | 2 | 1 | 2 | 2 |
| DR3.3 | Enumerate the indications for and describe the various modalities of treatment of psoriasis including topical, systemic and phototherapy | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| Topic | Lichen planus | | | | | · · · | | |
| DR4.1 | Identify and distinguish lichen planus lesions from other causes | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR4.2 | Enumerate and describe the treatment modalities for lichen planus | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| Topic | Scabies | | | | | | | |
| DR5.1 | Describe the etiology, microbiology, pathogenesis, natural history, clinical features, presentations and complications of scabies in adults and children | 3 | 0 | 2 | 1 | 2 | 2 | 2 |
| DR5.2 | Identify and differentiate scabies from other lesions in adults and children | 3 | 0 | 2 | 2 | 2 | 3 | 2 |
| DR5.3 | Enumerate and describe the pharmacology, administration and adverse reaction of pharmacotherapies for scabies | 3 | 0 | 2 | 2 | 2 | 2 | 3 |
| Topic | Pediculosis | | 1 | | | | 1 | 1 |
| DR6.1 | Describe the etiology pathogenesis and diagnostic features of pediculosis in adults and children | 3 | 0 | 2 | 2 | 2 | 2 | 2 |

| | Course outcome | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 |
|--------|---|-----------|----------|--------------|---------------------|--------------|---------------------|----------------|
| | | Clinician | Leader | Communicator | Lifelong learner | Professional | Critical thinker | Resear cher |
| DR6.2 | Identify and differentiate | 3 | 0 | 2 | 2 | 2 | 3 | 2 |
| | pediculosis from other skin | | | | | | | |
| | lesions in adults and children | | | | | | | |
| Торіс | Fungal infection | | | | | | | |
| DR 7.1 | Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of dermatophytes in adults and children | 3 | 0 | 2 | 1 | 2 | 2 | 2 |
| DR7.2 | Identify Candida species in fungal scrapings and KOH mount | 3 | 0 | 1 | 2 | 1 | 2 | 2 |
| DR7.3 | Describe the pharmacology and | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| | action of antifungal (systemic and topical) agents. Enumerate | | | | | | | |
| | side effects of antifungal therapy | | | | | | | |
| Topic | Viral infection | 2 | <u>^</u> | | | | | 2 |
| DR8.1 | Describe the etiology, microbiology, pathogenesis and clinical presentations and diagnostic features of common viral infections of the skin in adults and children | 3 | 0 | 2 | 1 | 2 | 2 | 3 |
| DR8.2 | Identify and distinguish herpes simplex and herpes labialis from other skin lesions | 3 | 0 | 3 | 2 | 2 | 3 | 2 |
| DR8.3 | Identify and distinguish herpes zoster and varicella from other skin lesions | 3 | 0 | 2 | 3 | 2 | 2 | 3 |
| DR8.4 | Identify and distinguish viral warts from other skin lesions | 3 | 0 | 2 | 2 | 1 | 2 | 2 |
| DR8.5 | Identify and distinguish molluscum contagiosum from other skin lesions | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| DR8.6 | Enumerate the indications, describe the procedure and perform a Tzanck smear | 3 | 0 | 1 | 1 | 2 | 1 | 2 |
| DR8.7 | Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for common viral illnesses of the skin | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| Topic | | 2 | 0 | 2 | 2 | | 2 | 2 |
| DR9.1 | Classify, describe the epidemiology, etiology, microbiology, | 3 | 0 | 3 | 2 | 2 | 2 | 2 |

| | pathogenesis, clinical presentations and | | | | | | | |
|--------|---|------------------|---------------|---------------------|----------------------------|-------------------------|----------------------------|-----------------------|
| | diagnostic features of Leprosy | | | | | | | |
| | Course outcome | PO1 Clinician | PO2 Leader | PO3 Communicator | PO4 Lifelong learner | PO5 Professiona l | PO6 Critical thinker | PO7 Resear cher |
| DR9.2 | Demonstrate (and classify based on) the clinical features of leprosy including an appropriate neurologic examination | 3 | 1 | 3 | 1 | 2 | 2 | 2 |
| DR9.3 | Enumerate the indications and observe the performance of a slit skin smear in patients with leprosy | 2 | 0 | 2 | 1 | 2 | 2 | 1 |
| DR9.4 | Enumerate, describe and identify lepra reactions and supportive measures and therapy of lepra reactions | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| DR9.5 | Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for various classes of leprosy based on national guidelines | 3 | 1 | 2 | 2 | 2 | 2 | 2 |
| DR9.6 | Describe the treatment of Leprosy based on the WHO guidelines | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| DR9.7 | Enumerate and describe the complications of leprosy and its management, including understanding disability and stigma. | 3 | 2 | 3 | 2 | 2 | 2 | 2 |
| Topic | Sexually transmitted diseases | | | | | | | |
| DR10.1 | Identify and classify syphilis based on the presentation and clinical manifestations | 3 | 1 | 3 | 1 | 2 | 2 | 2 |
| DR10.2 | Identify spirochete in a dark ground microscopy | 2 | 0 | 2 | 0 | 1 | 2 | 2 |
| DR10.3 | Enumerate the indications and describe the pharmacology, administration and adverse reaction of pharmacotherapies for syphilis | 3 | 1 | 2 | 2 | 2 | 2 | 2 |
| DR10.4 | Describe the prevention of congenital syphilis | 2 | 2 | 2 | 1 | 2 | 2 | 2 |
| DR10.5 | Counsel in a non-judgemental | 2 | 1 | 3 | 1 | 2 | 2 | 1 |

| | and empathetic manner patients on prevention of sexually transmitted disease | | | | | | | |
|------------------|--|------------------|---------------|---------------------|----------------------------|--------------------------------|----------------------------|-----------------------|
| | Course outcome | PO1 Clinician | PO2 Leader | PO3 Communicator | PO4 Lifelong learner | PO5 Professiona l | PO6 Critical thinker | PO7 Resear cher |
| DR10.6 | Describe the etiology, diagnostic and clinical features of non- syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV) | 3 | 1 | 3 | 2 | 2 | 2 | 2 |
| DR10.7 | Identify and differentiate based on the clinical features non- syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV) | 3 | 0 | 3 | 0 | 2 | 2 | 1 |
| DR10.8 | Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the non- syphilitic sexually transmitted diseases (chancroid, donovanosis and LGV) | 2 | 0 | 2 | 3 | 2 | 2 | 3 |
| DR10.9 | Describe the syndromic approach to ulcerative sexually transmitted disease | 3 | 0 | 2 | 1 | 2 | 1 | 2 |
| DR10.10 | Describe the etiology, diagnostic and clinical features and management of gonococcal and non- gonococcal urethritis | 3 | 0 | 3 | 3 | 2 | 3 | 2 |
| DR10.11 Topic | Describe the etiology, diagnostic and clinical features and management of vaginal discharge HIV | 3 | 0 | 3 | 3 | 2 | 3 | 2 |
| DR11.1 | HIV Describe the etiology, | 3 | 0 | 3 | 3 | 2 | 2 | 2 |
| | pathogenesis and clinical features of the dermatologic manifestations of HIV and its complications including opportunistic infections | | | | | | | 2 |
| DR11.2 | Identify and distinguish the dermatologic manifestations of HIV, its complications, opportunistic infections and adverse reactions | 3 | 0 | 3 | 2 | 2 | 2 | 1 |
| DR11.3 | Enumerate the indications and describe the pharmacology, | 2 | 1 | 2 | 2 | 3 | 3 | 2 |

| adverse reaction of a pharmaculospheraphes for densities in all TIVPOI ClinicianPO2 LeaderPO3 CommunicatorPO4 Lifelong learnedPO5 ProfessionaPO6 CriticalPO7 Resear CriticalTopic Dermatitis and eczema IDR12.1Dermatitis and eczema eczema01013133DR12.2Dectrification of a constraint eczema and differentia et from light3121332DR12.3Identify eczema and differentia et from light3023030DR12.4Enumerate the indications and uging eczema and identified indications and alverse reactions of drug sues of it erythroderma. Discuss the testingtish from other skin lesions3023232DR12.5Enumerate and identify explored eczema reactions of drug supplications from other skin lesions2032221DR12.6Edentify and distinguish explored eczema phares of i erythroderma. Discuss in lesions2032221DR12.6Edentify and distinguish fixed skin lesions20322221DR12.6Edentify and distinguish fixed skin lesions20322220DR12.6Edentify and distinguish fixed skin lesions20312220DR13.1 <t< th=""><th></th><th>administration and</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></t<> | | administration and | | | | | | | |
|--|--------|--------------------------------|----------|--------|--------------|---------|-----|----------|-------|
| pharmacoherapies for demastologic lesions in HIVPO1PO2PP03 LearnerPP05 ProfessionaPP05 ProfessionaPP07 Resear Critical linkerPP07 Resear timePP07 Resear LearnerPP05 ProfessionaPP07 Critical LearnerPP07 Resear LearnerPP05 ProfessionaPP07 Critical LearnerPP07 Resear LearnerPP05 ProfessionaPP07 Critical Resear LearnerPP07 Resear LearnerPP07 Resear LearnerPP05 Professiona LearnerPP07 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Resear LearnerPP03 Res | | | | | | | | | |
| dermatologic lesions in HIVPO1 ClinicalPO2 LeaderPO3 CommunicationPO4 LeaderPO3 CommunicationPO4 LeaderPO3 CommunicationPO4 LeaderPO4 CommunicationPO3 LeaderPO4 PO5 CommunicationPO5 PO6 LeaderPO6 PO7 CommunicationPO7 CommunicationPO3 LeaderPO3 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO6 LeaderPO7 CommunicationPO7 LeaderPO3 LeaderPO3 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO3 LeaderPO3 LeaderPO4 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO4 LeaderPO3 LeaderPO4 LeaderPO3 Leader <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<> | | | | | | | | | |
| HIVImage: point of the problem of the pro | | | | | | | | | |
| Course outcomePO1 ClinicianPO2 LeaderPO3 CommunicatorPO4 Lifelong learnerPO5 Professional lPO6 Critical messional lPO7 Critical messional lPO6 Critical messional learnerPO7 Lifelong learnerPO6 Lifelong learnerPO7 Professional lPO6 Critical messional limited messional limitedPO3 Lifelong learnerPO6 Lifelong learnerPO6 Lifelong learnerPO6 Lifelong learnerPO6 Lifelong learnerPO6 Lifelong learnerPO7 Critical messional lifelong learnerPO6 Lifelong Lifelong learnerPO6 Lifelong <b< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></b<> | | | | | | | | | |
| Image: Second | | | PO1 | DO3 | DO3 | PO4 | DO5 | DO6 | DO7 |
| Topic Dermaintis and eczema enter Ithiker eher DR12.1 Describe the actiopathogenesis of eczema 1 0 1 3 1 3 3 2 DR12.2 Identify eczema and differentiate it from lichentification and changes of aging 3 1 2 1 3 3 2 1 DR12.3 Classify and grade eczema 2 0 3 0 3 2 3 2 DR12.4 Enumerate the indications and dvarse reactions of drugs used in the treatment of eczema 3 1 2 3 2 3 2 DR12.5 Define crythroderma. 3 1 2 3 2 3 2 DR12.6 Define crythroderma. 3 1 2 3 2 3 2 DR12.6 Define crythroderma. 3 1 2 0 3 2 2 2 1 discore region and distinguish fued distinguish fued erglobal distinguish fued distinguish fued erglobal distinguish fued erglob | | Course outcome | | | - | | - | | |
| | | | Chincian | Ltauti | Communicator | 0 | | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Topic | Dermatitis and eczema | | | | icarner | | tilliker | ciici |
| orecominor <tho< td=""><td></td><td></td><td>1</td><td>0</td><td>1</td><td>3</td><td>1</td><td>3</td><td>3</td></tho<> | | | 1 | 0 | 1 | 3 | 1 | 3 | 3 |
| differentiate it from lichenification and changes of agingImage: Construct of the second | | | 1 | 0 | 1 | 5 | 1 | 5 | 5 |
| lichenification and changes of agingIIIIIDR12.3Classify and grade eczema20303030DR12.4Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema3023232DR12.5Define crythroderma, the causes of erythroderma. Discuss the treatment3123232DR12.6Identify and distinguish skin lesions2032221DR12.7Identify and distinguish skin lesions2032221DR12.7Identify and distinguish skin lesions2032221DR12.7Identify and distinguish rescibilative dermatitis from other skin lesions2032221DR12.7Identify and distinguish rescibilative dermatitis from other skin lesions2032220DR13.2Demonstrate the Tzanck test, area of involvement of vesicubullous lesions30312220DR13.3Calculate the body surface area of involvement of vesicubullous lesions30312222DR13.4Describe the tiology, pathogenesis and clinical precipiting faatures and classification of Ufurcirai and angioedema3 <t< td=""><td>DR12.2</td><td>Identify eczema and</td><td>3</td><td>1</td><td>2</td><td>1</td><td>3</td><td>3</td><td>2</td></t<> | DR12.2 | Identify eczema and | 3 | 1 | 2 | 1 | 3 | 3 | 2 |
| agingAAAADR12.3Classify and grade eczema2030330DR12.4Enumerate hidications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema3023232DR12.5Define crythroderma. Enumerate and identify the causes of erythroderma. Discuss312323232DR12.6Identify and distinguish explorations and Steven Johnson syndrome from other skin lesions20322211DR12.7Identify and distinguish fixed area of involvement of sign and bulla spread area of involvement of explorations20322211DR13.3Calculate the body surface area of involvement of explorations303030303030DR13.3Calculate the body surface area of involvement of explorations30312200303000DR13.3Calculate the body surface area of involvement of elsions3031222220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions303122222222222222< | | differentiate it from | | | | | | | |
| agingAAAADR12.3Classify and grade eczema2030330DR12.4Enumerate hidications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema3023232DR12.5Define crythroderma. Enumerate and identify the causes of erythroderma. Discuss312323232DR12.6Identify and distinguish explorations and Steven Johnson syndrome from other skin lesions20322211DR12.7Identify and distinguish fixed area of involvement of sign and bulla spread area of involvement of explorations20322211DR13.3Calculate the body surface area of involvement of explorations303030303030DR13.3Calculate the body surface area of involvement of explorations30312200303000DR13.3Calculate the body surface area of involvement of elsions3031222220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions303122222222222222< | | lichenification and changes of | | | | | | | |
| DR12.3Classify and grade eczema2030330DR12.4Enumerate the indications and dverse reactions of drugs used in the treatment of eczema3023232DR12.5Define erythroderma. Enumerate an identify the causes of erythroderma. Discuss the treatment312323232DR12.6Identify and distinguish exfoliative dermatitis from other skin lesions31232211DR12.7Identify and distinguish fixed drug eruptions and Steven plonknos syndrome from other skin lesions20322211DR13.2Demonstrate the Traneck test, nikoky sign and bulla spread sign303033011 </td <td></td> <td>aging</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | aging | | | | | | | |
| DR12.4 Enumerate the indications and describe the pharmacology, indications and adverse reactions of drugs used in the treatment of eczema 3 0 2 3 2 3 2 DR12.5 Define erythroderma. Discuss the treatment of eczema 3 1 2 3 2 3 2 DR12.6 Define erythroderma. Discuss the treatment 3 1 2 3 2 3 2 DR12.6 Identify and distinguish even skin lesions 2 0 3 2 2 1 DR12.7 Identify and distinguish fixed skin lesions 2 0 3 2 2 1 DR12.6 Identify and distinguish fixed skin lesions 2 0 3 2 2 1 DR12.7 Identify and distinguish fixed skin lesions 2 0 3 2 2 1 DR12.7 Identify and bulls from vesicles 2 0 3 2 2 1 DR12.6 Identify and bulls grad bulls spread sign 3 0 3 0 3 0 DR13.1 Distinguish uricaria angioedema | DR12.3 | | 2 | 0 | 3 | 0 | 3 | 3 | 0 |
| indications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatmentindications and adverse reactions of drugs used in the treatmentindications reactionsindicationsindicationsindications reactionsindicationsindicationsindications reactionsindications reactionsindicationsindications | DR12.4 | Enumerate the indications and | 3 | 0 | 2 | 3 | 2 | 3 | 2 |
| indications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatment of eczemaindications and adverse reactions of drugs used in the treatmentindications and adverse reactions of drugs used in the treatmentindications reactionsindicationsindicationsindications reactionsindicationsindicationsindications reactionsindications reactionsindicationsindications | | describe the pharmacology, | | | | | | | |
| reactions of drugs used in the treatment of eczemaImage: constraint of the causes of enviroderma. Discuss the treatment3123232DR12.5Define erythroderma. Enumerate and identify the causes of erythroderma. Discuss the treatment312323232DR12.6Identify and distinguish exfoliative demantitis from other skin lesions2032221DR12.7Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other sign2032221DR13.1Distinguish blual from vesicles sign2022200DR13.3Calculate the body surface area of involvement of vesiculbullus lesions3031220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions30312222DR14.1Describe the etiology, pathogenesis and clinical precipiting features and classification of Urticaria and angioedema3022222222DR14.2Identify and distinguish urticarial from other ksin lesions2022232222DR13.4Identify and distinguish urticarial from other ksin lesions302222222DR14.1Ide | | | | | | | | | |
| Image: constraint of eczemaImage: constraint of eczemaImage: constraint of eczemaImage: constraint of eczemaDR12.5Define erythroderma. Enumerate and identify the causes of erythroderma. Discuss the treatmentImage: constraint of eczemaImage: constraintoImage: constraint of ecze | | | | | | | | | |
| DR12.5Define erythroderma. Enumerate and identify the causes of erythroderma. Discuss the treatment3123232DR12.6Identify and distinguish exfoliative dermatifis from other skin lesions2032221DR12.7Identify and distinguish erythroderma. Discuss the treatment2032221DR12.7Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other skin lesions2032221DR13.7Distinguish bulla from vesicles sign2022220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign3031220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema20222222DR14.2Identify and distinguish urticarial from other skin lesions20223222 | | - | | | | | | | |
| Enumerate and identify the causes of erythroderma. Discuss the treatmentImage: Constraint of the causes of erythroderma. Discuss the causes of erythroderma. Discuss the treatmentImage: Constraint of the causes of erythroderma. Discuss the erythroderma. Discuss <br< td=""><td>DR12.5</td><td></td><td>3</td><td>1</td><td>2</td><td>3</td><td>2</td><td>3</td><td>2</td></br<> | DR12.5 | | 3 | 1 | 2 | 3 | 2 | 3 | 2 |
| the causes of erythroderma. Discuss the treatmentImage: constraint of the causes of erythroderma. Discuss the treatmentImage: constraint of the causes of erythroderma. Discuss the treatmentImage: constraint of the cause of cause of the cause of the cause of the treatmentImage: constraint of the cause of the cause of the cause of the treatmentImage: constraint of the cause of the cause of the cause of the cause of the treatmentImage: constraint of the cause of the cause o | | - | | | | | | | |
| erythroderma. Discuss the treatmentImage: Constraint of the treatmentImage: Constraint of the treatmentImage: Constraint of the treatmentDR12.6Identify and distinguish skin lesions203221DR12.7Identify and distinguish fixed drug cruptions and Steven Johnson syndrome from other skin lesions2032221DR12.7Identify and distinguish fixed drug cruptions and Steven Johnson syndrome from other skin lesions2032221DR13.1Distinguish bulla from vesicles sign2022220DR13.2Demonstrate the Tzanck test, sign303303030DR13.3Calculate the body surface area of involvement of vesiculobullous lesions303122222DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3022222222DR14.1Describe the citology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema2022232222DR14.2Identify and distinguish urticarial from other skin lesions202232222 | | | | | | | | | |
| IndexInternation | | | | | | | | | |
| DR12.6Identify and distinguish exfoliative dematitis from other skin lesions2032221DR12.7Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other skin lesions2032221 TopicVesicobullous lesions DR13.1Distinguish bulla from vesicles202220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign3031220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220 TopicUrticaria Angioedema DR14.1Describe the citology, pathogenesis and clinical precipitating features and classification of Urticaria and angiocedema202222222DR14.2Identify and distinguish urticarial from other skin lesions20223222 | | - | | | | | | | |
| exfoliative dermatitis from other skin lesionsexfoliative dermatitis from other skin lesionsexfoliative dermatitiesfrom other skin lesionsexfoliative dermatities | DR12.6 | | 2 | 0 | 3 | 2 | 2 | 2 | 1 |
| DR12.7Identify and distinguish fixed drug eruptions and Steven Johnson syndrome from other skin lesions2032221TopicVesicobullous lesionsDR13.1Distinguish bulla from vesicles202220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign3031220DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220TopicUrticaria Angioedema30222220DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema30222222DR14.2Identify and distinguish urticarial from other skin lesions20223222 | | | | | _ | | | | |
| drug eruptions and Steven Johnson syndrome from other skin lesionsImage: Steven Steven of the skin lesionsImage: Steven other skin lesionsImage: Steven other skin lesionsTopicVesicobullous lesionsImage: Steven other skin lesionsImage: Steven other skin lesionsImage: Steven other steven other skin lesionsImage: Steven other steven othe | | | | | | | | | |
| Johnson syndrome from other skin lesionsJohnson syndrome from other skin lesionsImage: Constraint of the skin lesionsImage: Constraint of the skin lesionsTopicVesicobullous lesionsImage: Constraint of the skin lesiont of the skin lesionsImage: Constraint of the skin lesiont of the skin lesionsImage: Constraint of the skin lesiont of | DR12.7 | | 2 | 0 | 3 | 2 | 2 | 2 | 1 |
| Skin lesionsImage: skin lesionsImage: skin lesionsImage: skin lesionsTopicVesicobullous lesionsImage: skin lesionsImage: skin lesionsImage: skin lesionsDR13.1Distinguish bulla from vesicles202220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign30303030DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220TopicUrticaria AngioedemaImage: skin lesions30222222DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema3022 | | | | | | | | | |
| TopicVesicobullous lesionsDR13.1Distinguish bulla from vesicles202220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign3030330DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema30222222DR14.2Identify and distinguish urticarial from other skin lesions20223222 | | | | | | | | | |
| DR13.1Distinguish bulla from vesicles2022220DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign30303030DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema30222222DR14.2Identify and distinguish urticarial from other skin lesions2022322 | | | | | | | | | |
| DR13.2Demonstrate the Tzanck test, nikolsky sign and bulla spread sign3030330DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220TopicUrticaria Angioedema03022222DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema3022222DR14.2Identify and distinguish urticarial from other skin lesions2022322 | | | | | | | • | | |
| nikolsky sign and bulla spread signImage: signImage: signIm | | | | | | | | | - |
| signImage: signImage: signImage: signImage: signImage: signDR13.3Calculate the body surface3031220area of involvement of vesiculobullous lesionsImage: signImage: sign | DR13.2 | | 3 | 0 | 3 | 0 | 3 | 3 | 0 |
| DR13.3Calculate the body surface area of involvement of vesiculobullous lesions3031220TopicUrticaria AngioedemaDR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema30222222DR14.2Identify and distinguish urticarial from other skin lesions2022322 | | | | | | | | | |
| area of involvement of vesiculobullous lesionsImage: Constraint of the second | DR13.3 | <u> </u> | 3 | 0 | 2 | 1 | 2 | 2 | 0 |
| Vesiculobullous lesionsImage: constraint of the second | DR15.5 | | 3 | 0 | 5 | 1 | 2 | 2 | 0 |
| TopicUrticaria AngioedemaDR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema3022222DR14.2Identify and distinguish urticarial from other skin lesions202222 | | | | | | | | | |
| DR14.1Describe the etiology, pathogenesis and clinical precipitating features and classification of Urticaria and angioedema30222222DR14.2Identify and distinguish urticarial from other skin lesions20222222 | Tonic | | | | | | | | |
| pathogenesis and clinical precipitating features and classification of Urticaria and angioedemaImage: Construction of Urticaria and angioedemaImage: Construction of Urticaria classification of UrticariaDR14.2Identify and distinguish urticarial from other skin lesions2022322 | | | 2 | Δ | 2 | n | 2 | n | 2 |
| precipitating features and classification of Urticaria and angioedemaImage: Classification of Urticaria and angioedemaImage: Classification of Urticaria classification of Urticaria classification of Urticaria and angioedemaImage: Classification of Urticaria classification of Urt | DR14.1 | | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| classification of Urticaria and angioedema </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | | | | | | | | | |
| and angioedemaImage: Constraint of the second s | | | | | | | | | |
| DR14.2Identify and distinguish urticarial from other skin lesions2022322 | | | | | | | | | |
| from other skin lesions | DR14 2 | | 2 | 0 | 2 | n | 2 | 2 | 2 |
| | DK14.2 | from other skin lesions | 2 | 0 | 2 | 2 | 3 | 2 | 2 |
| | DR14.3 | | 2 | 0 | 1 | 1 | 2 | 2 | 2 |
| | | | _ | - | | - | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| | Course outcome | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 |
|--------|--|-----------|--------|--------------|---------------------|------------------|---------------------|----------------|
| | | Clinician | Leader | Communicator | Lifelong learner | Professiona l | Critical thinker | Resear cher |
| DR14.4 | Identify and distinguish angioedema from other skin lesions | 2 | 0 | 2 | 1 | 2 | 2 | 2 |
| DR14.5 | Enumerate the indications and describe the pharmacology indications and adverse reactions of drugs used in the urticaria and angioedema | 2 | 1 | 2 | 2 | 2 | 2 | 2 |
| Topic | Pyoderma | | 1 | 1 | | 1 | | 1 |
| DR15.1 | Identify and distinguish folliculitis impetigo and carbuncle from other skin lesions | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| DR15.2 | Identify staphylococcus on a gram stain | 2 | 0 | 2 | 2 | 2 | 2 | 2 |
| DR15.3 | Enumerate the indications and describe the pharmacology, indications and adverse reactions of topical and systemic drugs used in treatment of pyoderma | 2 | 0 | 2 | 2 | 3 | 2 | 2 |
| DR15.4 | Enumerate the indications for surgical referral | 2 | 1 | 3 | 3 | 2 | 2 | 1 |
| Topic | Collagen vascular diseases | | 0 | | | | | |
| DR16.1 | Identify and distinguish skin lesions of SLE | 2 | 0 | l | 2 | 3 | 2 | 1 |
| DR16.2 | Identify and distinguish Raynaud's phenomenon | 2 | 0 | 1 | 2 | 2 | 2 | 2 |
| Торіс | Nutritional deficiencies and Skin | | | | | | | |
| DR17.1 | Enumerate and identify the cutaneous findings in vitamin A deficiency | 2 | 0 | 1 | 2 | 2 | 2 | 2 |
| DR17.2 | Enumerate and describe the various skin changes in Vitamin B complex deficiency | 2 | 0 | 1 | 2 | 2 | 2 | 2 |
| DR17.3 | Enumerate and describe the various changes in Vitamin C deficiency | 3 | 0 | 2 | 2 | 2 | 2 | 2 |
| DR17.4 | Enumerate and describe the various changes in Zinc deficiency | 3 | 0 | 2 | 2 | 2 | 2 | 1 |
| Topic | Systemic diseases and skin | | - | | | | | I . |
| DR18.1 | Enumerate the cutaneous features of Type 2 diabetes | 2 | 0 | 1 | 2 | 2 | 2 | 1 |
| DR18.2 | Enumerate the cutaneous features of hypo/hyper-thyroidism | 2 | 0 | 2 | 2 | 2 | 2 | 1 |